LONSURF is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Gemmis is indicated for the treatment of non-small cell lung cancer, pancreatic cancer, bladder cancer and biliary tract cancer. Gemmis is indicated in combination with paclitaxel for anthracycline-treated failure locally-recurred inoperable breast cancer or metastatic breast cancer after failure of prior anthracycline-containing adjuvant or metastatic chemotherapy. Gemmis is indicated in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy. Biliary tract cancer.
Irino is indicated for the treatment of patients with advanced colorectal cancer:
1. In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.
2. As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.
3. In combination with cetuximab, it is used to treat patients with KRAS wild-type metastatic colorectal cancer who have failed cytotoxic therapy with irinotecan and have epithelial growth factor receptor (EGFR) phenotype. (See Pharmacodynamic Properties)
4. In combination with 5 fluorouracil, folinic acid, and bevacizumab as the first-line treatment for patients with metastatic colorectal or rectal cancer.
5. In combination treatment with capecitabine as first-line treatment for patients with metastatic colorectal cancer.
6. In combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFIRINOX) as the first-line treatment for metastatic pancreatic cancer.
7. For patients with unresectable locally advanced and recurrent/metastatic gastric cancer.
Breast cancer, non-small cell lung cancer, prostate cancer, head and neck cancer, gastric adenocarcinoma.
Arsenic trioxide is indicated for the induction of remission and consolidation of acute promyelocytic leukemia characterized by t (15,17) translocation or PML/RAR-alpha gene expression, in patients who are refractory to or have relapsed from retinoid and anthracycline chemotherapy.
The effect of Trioxide on other acute myeloid leukemias has not been studied.
1. Lenalidomide in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplantation (ASCT).
2. To be used in combination with dexamethasone for the treatment of multiple myeloma (MM) patients who have received at least one prior therapy.
1. Used in combination with other cancer treatment drugs for untreated multiple myeloma (MM) patients and who have received at least one treatment modality or patients with advanced multiple myeloid cancer who are not suitable for bone marrow transplantation.
2. For Mantle Cell Lymphoma (MCL) patients.
Painkyl is an opioid analgesic indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Patients considered opioid tolerant are those who are taking at least: 60 mg oral morphine/day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for one week or longer.
Granisetron extended-release subQ injection is indicated for the prevention of acute and delayed chemotherapy-associated nausea and vomiting in patients receiving regimens with an anthracycline in combination with cyclophosphamide.
It may be used for initial and repeat chemotherapy courses, and must be used in combination with other antiemetics (eg, dexamethasone, neurokinase-1 receptor antagonists).
Bone metastases from solid tumors: Treatment of documented bone metastases from solid tumors (in conjunction with standard antineoplastic therapy); prostate cancer should have progressed following treatment with at least one hormonal therapy.
Hypercalcemia of malignancy: Treatment of hypercalcemia (albumin-corrected serum calcium ≥12 mg/dL) of malignancy. Multiple myeloma: Treatment of osteolytic lesions of multiple myeloma.